Additionally, the efficacy of ADCs in ERBB2-amplified NSCLC varied across different clinical trials (5, 6, 49); however, a recent study has revealed that the overall response rate by RECIST of T-DM1 in ERBB2-amplified NSCLC was 50% (5/10) (6), suggesting ERBB2 amplification was also a promising target. Here, ERBB2 is linked to non-small cell lung carcinoma.